$IMMU - On our trading list, and we would accumulate some. Analyst starts coverage with a $26 target. Cites the upcoming FDA catalyst.Immunomedics initiated with a Buy at BofA/MerrillBofA/Merrill analyst Tazeen Ahmad initiated coverage of Immunomedics with a Buy rating and $26 price target. The company recently refiled its Biologic License Application for sacituzumab govitecan after addressing manufacturing issues, and the FDA's potential acceptance in January is a "key catalyst," Ahmad tells investors in a research note. The analyst estimates risk adjusted peak sales of $687M from triple negative breast cancer in 2029. $IMMU, Immunomedics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page